Study of SCY-635, Pegasys and Copegus in Hepatitis C
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study will examine the effectiveness of 28 days of triple combination therapy including
SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An
additional 20 weeks of treatment with the currently approved standard of care will be offered
to all participants. The Week 24 visit will be the last on-study visit. After the Week 24
visit, all subjects with undetectable HCV RNA will be given the option to continue treatment
with standard of care for an additional 24 weeks (out to Week 48) under the care of their
Principal Investigator.